Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JCAR017 + iberdomide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
**JCAR017 + iberdomide** is an investigational combination therapy involving JCAR017 (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, and iberdomide (CC-220), a cereblon E3 ligase modulator (CELMoD) small molecule agent. JCAR017 is manufactured as a defined composition of CD4+ and CD8+ CAR T cells designed to target and destroy CD19-expressing malignant B cells via autologous cell therapy. Iberdomide acts as a CELMoD agent, enhancing tumoricidal and immune-stimulatory effects in hematologic malignancies, particularly by modulating the cereblon (CRBN) substrate receptor to induce anti-cancer immune activation and direct tumor cell apoptosis. The combination is primarily being explored in relapsed/refractory B-cell malignancies[1][7][9].
- Other names
- lisocabtagene maraleucel + iberdomide
02
Targets
CD19 (B lymphocyte antigen CD19)CRBN (Cereblon)
Beyond the preview
Go deeper on JCAR017 + iberdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCAR017 + iberdomide.